Breckenridge Pharmaceutical Inc., of Boca Raton, Fla., said the FDA approved its abbreviated new drug application for Gabapentin Oral Solution 250 mg per 5 mL, a generic of Neurontin (gabapentin, Pfizer Inc.), as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients with epilepsy.